A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Trial Profile

A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs AU 011 (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions
  • Sponsors Aura Biosciences
  • Most Recent Events

    • 23 Jul 2018 According to an Aura Biosciences media release, Aura plans to complete the enrollment of this trial in October.
    • 23 Jul 2018 Results published in the Aura Biosciences Media Release
    • 23 Jul 2018 According to an Aura Biosciences media release, data from this study were presented at the 36th annual American Society of Retina Specialists (ASRS) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top